Highlights GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:21:31 15/05/2026 BST			5-day change	1st Jan Change
1,894.25 ^GBX	+1.16%		+2.97%	+4.01%

05-14	Morningstar Upgrades GSK to Buy Rating	MT
05-14	UK Stocks-Factors to watch on May 14	RE

Highlights

05-13	For interim dividend	FA
05-12	Artios Pharma Limited and GSK Enter Clinical Trial Collaboration Agreement	CI
05-11	GSK plc and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Enter Exclusive Collaboration for Bepirovirsen in China	CI
05-11	GSK Teams Up with Sino Biopharmaceutical for Distribution of Potential Hepatitis B Drug in China	MT
05-11	GSK, Sino Biopharmaceutical Unit Collaborate for China Launch of Bepirovirsen	MT
05-11	GSK agrees China hepatitis B deal as kicks off last tranche of buyback	AN
05-11	Compass lifts outlook as GSK expands in China	AN
05-11	GSK Kicks Off Fifth Tranche of GBP2 Billion Share Repurchase Program	MT
05-11	GSK Signs Chronic Hepatitis B Drug's Marketing Deal With China's Sino Biopharmaceutical	MT
05-07	Halozyme, GSK Enter Collaboration, Licensing Agreement	MT
05-07	Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets	CI
05-05	GSK Price Target Cut as Bernstein Notes Near-term Catalysts	MT
05-01	UK Regulator Approves GSK's Lynavoy as Treatment for Liver Disease Itch	MT
05-01	UK Regulator Clears GSK's Linerixibat for Treatment of Biliary Tract Disease-related Itch	MT
04-30	GSK plc: A beat isn't enough; markets expected an outlook upgrade
04-29	UK Shares Fall as Earnings Pour In, Geopolitical Tensions Rise	MT
04-29	GSK CEO Miels says there is no immediate change to launch sequence or portfolio from MFN policy in U.S.	RE
04-29	GSK plc Declares First Interim Dividend for First Quarter of 2026, Payable on 9 July 2026	CI
04-29	Tranche Update on GSK plc's Equity Buyback Plan announced on February 5, 2025.	CI
04-29	GSK CEO Miels: We'd love to do more deals in vaccines, but it's just not as much innovation in vaccines	RE
04-29	GSK plc Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-29	GSK CEO Miels on U.S. pricing policy: We need to see where this settles out	RE
04-29	GSK CEO Miels: identified 50 programmes that could co could accelerate, expects to provide details in Q2 - conf call	RE
04-29	GSK CEO Miels: Have launched asthma drug Exdensur in Germany and Japan - conf call	RE
04-29	GSK Q1 Core Earnings, Sales Increase; 2026 Core EPS, Sales Outlook Maintained	MT